SCHEMBL3524909

SCHEMBL3524909

CCOC(=O)C(C)OCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1c(C)noc1C

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.43
LMNA P02545 6/20 0.43
ALDH1A1 P00352 3/20 0.43
POLB P06746 2/20 0.41
ACLY P53396 1/20 0.39
GAA P10253 3/20 0.39
HTT P42858 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.38
PKM P14618 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HCRTR1 O43613 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524515 0.78 SMN1; SMN2 (0.48) MAPTLMNAALDH1A1HTTTSHR
SCHEMBL3523131 0.78 POLB (0.46) MAPTLMNAALDH1A1POLBACLY
SCHEMBL3528287 0.77 NPSR1 (0.45) MAPTLMNAALDH1A1POLBGAA
SCHEMBL3523093 0.77 HTT (0.48) MAPTLMNAALDH1A1GAAHTT
SCHEMBL3526713 0.77 ALDH1A1 (0.46) MAPTLMNAALDH1A1POLBGAA
SCHEMBL3524812 0.77 ALDH1A1 (0.46) MAPTLMNAALDH1A1POLBGAA
SCHEMBL3528196 0.74 PTGES2 (0.44) ALDH1A1HTTPKMSMN1; SMN2KMT2A
SCHEMBL3524927 0.72 MAOB (0.36) MAPTLMNAALDH1A1POLBGAA
SCHEMBL3528030 0.72 MAOB (0.36) MAPTLMNAALDH1A1POLBGAA
SCHEMBL3523608 0.69 ALDH1A1 (0.43) MAPTLMNAALDH1A1POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP MAPT 214/4885LMNA 849/4885ALDH1A1 1607/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG MAPT 730/4885LMNA 1980/4885ALDH1A1 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.